Vor Biopharma Inc (VOR) Prix

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Boston, Massachusetts and currently employs 159 full-time employees. The company went IPO on 2021-02-05. The firm is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.